Compare NOW & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NOW | VRTX |
|---|---|---|
| Founded | 2004 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | EDP Services |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.2B | 115.7B |
| IPO Year | 2012 | 2006 |
| Metric | NOW | VRTX |
|---|---|---|
| Price | $116.78 | $499.96 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 31 | 27 |
| Target Price | $202.70 | ★ $526.79 |
| AVG Volume (30 Days) | ★ 17.0M | 1.3M |
| Earning Date | 04-29-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 836.54 |
| EPS | 1.67 | ★ 15.32 |
| Revenue | $1,933,026,000.00 | ★ $2,488,652,000.00 |
| Revenue This Year | $21.52 | $10.79 |
| Revenue Next Year | $18.41 | $10.14 |
| P/E Ratio | $74.28 | ★ $29.80 |
| Revenue Growth | 39.02 | ★ 46.20 |
| 52 Week Low | $98.00 | $362.50 |
| 52 Week High | $1,057.39 | $519.68 |
| Indicator | NOW | VRTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.97 | 59.25 |
| Support Level | $98.59 | $426.38 |
| Resistance Level | $136.63 | $503.88 |
| Average True Range (ATR) | 4.67 | 15.97 |
| MACD | 7.30 | 0.48 |
| Stochastic Oscillator | 68.68 | 81.77 |
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management, expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.